The initial rollout of a COVID-19 vaccine in the UK is getting very close indeed. To support this effort, the Government has appointed Nadim Zahawi MP as Minister for Vaccine Deployment in the Department of Health and Social Care (DHSC).
Amid gloomy economic predictions and rising public borrowing fuelled by the pandemic, the Chancellor delivered a one-year government spending settlement with investment in jobs and infrastructure to reassure a nervous nation.
LUNAC Therapeutics Ltd (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants with minimal risk of bleeding, announces that it has appointed Carl Sterritt as Chief Executive Officer.
Dr Sally Price, Head of Cell and Translational Science at Medicines Discovery Catapult (MDC) has been named in BioBeat’20 Movers & Shakers in BioBusiness 2020.
Strengthening Selvita’s position as one of the largest preclinical contract research organizations in Europe - Acquisition substantially expands Selvita’s integrated drug discovery services offering - Transaction will almost double Selvita’s revenues - Enterprise value of € 31.2M to be paid in cash - Fidelta to continue performing drug discovery services for Galapagos for the next five years
The news that we’ve all been waiting for is out today, from the UK-sourced Oxford University and AstraZeneca COVID-19 vaccine. The great news is that the vaccine works in Phase III clinical trials. For an industry audience it is worth digging into the complex dataset.
The BioIndustry Association's Rare Disease Industry Group (RDIG) has today launched A Rare Chance for Reform in collaboration with PwC, calling for action to ensure that patients are able to access innovative medicines for rare diseases.
Sell or redeploy equipment from multiple sites within your company with EquipNet’s Surplus Asset Management Program.
Abzena, a global partner research organization for integrated bench to market solutions for biologics and bioconjugates, has announced upgrades of its chemistry GMP suites.
Insufficient government funding is putting the UK’s pipeline of future biomedical innovations at risk, according to data revealed in a Freedom of Information (FOI) request.